Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Scott Glenn

Lauren G. Otsuki

Oncternal Therapeutics, Inc.

FiercePharma provides news and information related to the pharmaceutical industry, including topics like vaccines, drug delivery, and manufacturing, self-described as highlighting corporations driving change in healthcare.

FiercePharma

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression.

The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers.

Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.

Oncternal Therapeutics

We’re #hiring a new Head of Preclinical and Translational Science in United States. Apply today or share this post with your network.

Metric
Company Name	Oncternal Therapeutics, Inc.	FiercePharma
Symbol	ONCT
MSH ID	COM:ONCTERNAL	COM:FIERCEPHARMA
Market	STOCKS	PRIVATE
Sector	Healthcare	Commercial & Professional Services
Industry	Biotechnology	Pharmaceuticals
Country	US	US
Stage
Employee Count	27
Website	oncternal.com	fiercepharma.com
LinkedIn	oncternal-therapeutics
Founders

Metric
Market Cap	21.66M
Enterprise Value
Monthly Web Traffic		484.53K
Web Traffic Growth		-0.10
Valuation
Raised Capital

Metric
Revenue	785K
Revenue (LTM)
Revenue (NTM)
Gross Profit	785K
EBITDA	-41.71M
Operating Income	-41.71M
Net Income	-39.48M
EPS	-13.43
Diluted EPS	-13.43
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.81
Operating Profit Margin	-20.41
EBITDA Margin	-53.14
Net Profit Margin	-19.49
Return on Equity	1.20
Return on Assets	-1.07
Return on Capital Employed	-1.32

COM:ONCTERNAL

Oncternal Therapeutics

Last Close

1.16

22/11 21:00

Market Cap

21.66M

Beta: -

Volume Today

22.02K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-13.60
P/B Ratio	-2.97
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	33.89
EV Multiple	-0.25

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding	0.00
Operating Cycle	293.86
Cash Conversion Cycle	232.41
Asset Turnover	0.08

Metric
Operating Cash Flow	-32.16M
Free Cash Flow	-32.16M
Cash Flow to Debt
Operating Cash Flow/Sales	-13.65
Free Cash Flow Yield	-1.24

Metric
Cash & Equivalents	6.70M
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization	0.01
Debt to Assets	0.01
Current Ratio	8.25
Quick Ratio	6.71

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue